A Phase 2 Double Blind Study to Evaluate Safety and Immunogenicity of Meningococcal Meningitis Serogroups A, C, Y and W-135 Polysaccharide Diphtheria Toxoid Conjugate Vaccine (NmVac4-A/C/Y/W-135-DT) Compared With a Licensed Vaccine

Trial Profile

A Phase 2 Double Blind Study to Evaluate Safety and Immunogenicity of Meningococcal Meningitis Serogroups A, C, Y and W-135 Polysaccharide Diphtheria Toxoid Conjugate Vaccine (NmVac4-A/C/Y/W-135-DT) Compared With a Licensed Vaccine

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2015

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Focus Therapeutic Use
  • Sponsors JN-International Medical Corporation
  • Most Recent Events

    • 04 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 May 2014 Planned End Date changed from 1 Oct 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
    • 16 May 2014 Planned primary completion date changed to 1 May 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top